Iterum Therapeutics requests Nasdaq hearing to appeal delisting; warns of possible wind-down

Iterum Therapeutics plc

On March 3, 2026, Iterum requested a hearing before Nasdaq Hearings Panel to appeal delisting for failure to maintain $1.00 bid price.
Hearing request automatically stays suspension scheduled for March 5, 2026, pending the hearing and any extension.
Company also fails to meet $35M minimum market value of listed securities requirement; compliance deadline June 9, 2026.
Evaluating strategic alternatives including possible wind-down, bankruptcy, licensing or sale of assets.
Company states limited ability to raise capital; shareholders very unlikely to receive distribution in a wind-down.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.